ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HALO Halozyme Therapeutics Incorporated

38.02
-0.36 (-0.94%)
Apr 17 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.36 -0.94% 38.02 18:24:12
Open Price Low Price High Price Close Price Previous Close
38.45 37.9817 38.78 38.02 38.38
more quote information »

Recent News

Date Time Source Heading
3/04/202415:13EDGAR2Form PRE 14A - Other preliminary proxy statements
2/28/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/28/202415:07EDGAR2Form 144 - Report of proposed sale of securities
2/27/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202415:08EDGAR2Form 144 - Report of proposed sale of securities
2/27/202407:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
2/20/202417:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/20/202415:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/20/202415:03EDGAR2Form 8-K - Current report
2/20/202415:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
2/16/202416:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/13/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/13/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/13/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/12/202405:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/08/202415:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
1/29/202415:15PRNUSHalozyme Announces Takeda Received European Commission..
1/23/202410:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
1/18/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/18/202407:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
1/17/202415:56EDGAR2Form 144 - Report of proposed sale of securities
1/17/202407:10EDGAR2Form 8-K - Current report
1/16/202415:26EDGAR2Form 144 - Report of proposed sale of securities
1/16/202407:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
1/16/202400:15PRNUSHalozyme Announces Roche Receives European Commission..
1/12/202408:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
1/05/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202318:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202315:40EDGAR2Form 144 - Report of proposed sale of securities
12/12/202315:21EDGAR2Form 144 - Report of proposed sale of securities
11/27/202307:00PRNUSHalozyme to Present at Upcoming Investor Conferences
11/16/202315:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/16/202308:00PRNUSHalozyme Announces argenx Receives European Commission..
11/15/202315:17EDGAR2Form 144 - Report of proposed sale of securities
11/14/202315:19EDGAR2Form 144 - Report of proposed sale of securities
11/06/202315:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/06/202315:04EDGAR2Form 8-K - Current report
11/06/202315:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
11/06/202306:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
10/30/202317:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
10/19/202306:15PRNUSPositive Topline Results Reported from Bristol Myers..
10/17/202318:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/17/202315:03EDGAR2Form 144 - Report of proposed sale of securities

Your Recent History

Delayed Upgrade Clock